Business Context and Reporting Period
This Form 8-K was filed by Lipocine Inc. on December 27, 2019. The report addresses a regulatory notice received from the Nasdaq Listing Qualifications Department regarding the company's continued listing status on The NASDAQ Capital Market under the symbol "LPCN".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock's closing bid price, which had remained below the minimum requirement of $1.00 per share for the last 30 consecutive trading days.
Material Changes
The material change reported is the receipt of a formal notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the sustained low bid price of the company's common stock. This notice does not result in immediate delisting, and trading continues uninterrupted.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-calendar-day period (until June 24, 2020) to regain compliance.
- Compliance Criteria: To resolve the deficiency, the closing bid price must reach at least $1.00 for a minimum of ten consecutive business days during the compliance period.
- Secondary Compliance Option: If the company fails to regain compliance by June 24, 2020, it may be afforded a second 180-day period. This requires meeting all other initial listing standards (excluding the bid price) and may necessitate a reverse stock split.
- Management Action: Management intends to actively monitor the stock price and consider available options, including a reverse stock split, to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of Lipocine Inc. (LPCN) to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to cure the deficiency.
- Track the company's status as the June 24, 2020 deadline approaches to determine if a second compliance period is required.
- Review subsequent filings for updates on the company's market value of publicly held shares, which is a requirement for the second compliance period.